Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 37Carcinoma, Non-Small-Cell Lung 23Uterine Cervical Neoplasms 22Melanoma 22Carcinoma, Renal Cell 18Endometrial Neoplasms 16Colorectal Neoplasms 15Carcinoma, Transitional Cell 15Triple Negative Breast Neoplasms 13Stomach Neoplasms 13Fallopian Tube Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Hepatocellular 10Pancreatic Neoplasms 9Breast Neoplasms 9Head and Neck Neoplasms 8Carcinoma, Ovarian Epithelial 8Carcinoma, Merkel Cell 8Small Cell Lung Carcinoma 7Prostatic Neoplasms 7Neoplasms 7Neoplasm Metastasis 7Lung Neoplasms 6Esophageal Neoplasms 6Cholangiocarcinoma 6Urinary Bladder Neoplasms 5Mesothelioma 5Lymphoma 4Carcinosarcoma 4Vulvar Neoplasms 3

Interventions

pembrolizumab 3poly ICLC 1osimertinib 1durvalumab 1cobimetinib 1atezolizumab 1advexin 1Vorinostat 1Papanicolaou Test 1Nivolumab 1Human Papillomavirus DNA Tests 1High-Intensity Focused Ultrasound Ablation 1Colposcopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × Nivolumab × Gynecologic × Clear all
NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡